Core Insights - NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment, reporting a business update and second quarter 2025 financial results [1][8] Business Highlights and Near-Term Milestones - The strategic acquisition of global rights for SIM0505, targeting CDH6, positions NextCure uniquely in the antibody-drug conjugate (ADC) field, with plans to dose the first patient in the U.S. this quarter [2][6] - NextCure is currently in cohort 4 of the Phase 1 trial for LNCB74 (B7-H4 ADC) and plans to provide updates on both SIM0505 and LNCB74 by Q4 2025, along with proof of concept data in the first half of 2026 [6][7] Financial Results - As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $35.3 million, down from $68.6 million as of December 31, 2024, primarily due to operational funding [5][15] - Research and development expenses for Q2 2025 were $24.1 million, an increase from $12.4 million in Q2 2024, largely due to $17.0 million in up-front license fees [13] - The net loss for Q2 2025 was $26.8 million, compared to a net loss of $15.4 million in Q2 2024, reflecting the impact of the license fee [13][14]

Core Viewpoint - NextCure, Inc. is advancing its clinical-stage biopharmaceutical efforts with the presentation of a Phase 1 study poster for LNCB74, a B7-H4 targeted antibody-drug conjugate, at the ASCO Annual Meeting, highlighting its potential in treating various advanced solid tumors [1][3]. Company Overview - NextCure, Inc. is focused on developing innovative cancer therapies for patients who do not respond to existing treatments, utilizing differentiated mechanisms such as antibody-drug conjugates, antibodies, and proteins [4]. Study Details - The Phase 1 study is evaluating LNCB74 as a monotherapy for advanced solid tumors, including platinum-resistant ovarian cancer, treatment-refractory breast cancer, endometrial cancer, biliary tract cancer, and squamous non-small cell lung cancer, with ongoing dose escalation [2][7]. - The study includes phases for dose escalation, dose expansion, and optimization, currently enrolling participants in the dose escalation phase [2][7]. Target and Efficacy - B7-H4 is identified as an attractive target for ADC therapy due to its high expression in multiple tumor types and limited expression in normal tissues, with LNCB74 showing a superior safety profile and potent anti-tumor activity in preclinical studies [3].